Pharmaceutical Market Europe • March 2026 • 36
APPOINTMENTS
BioDuro
Andrew Thomas
BioDuro has appointed Andrew Thomas as Scientific Advisor. Thomas was formerly Global Head of Medicinal Chemistry, Small Molecule Research at Roche, where he was a member of the Therapeutics Modalities Leadership Team and led global teams responsible for advancing innovative drug discovery programmes across multiple therapeutic areas. More recently, he has managed two investment funds focused on Swiss technology growth companies.
Thomas will provide strategic guidance to both clients and the company’s scientific and operational teams, helping to strengthen the company’s capabilities in innovative drug discovery and development.
Thomas is focused on transforming impactful innovation in the healthcare sector and has published more than 100 patents, peer-reviewed journals and books.
N4 Pharma
David Solomon
N4 Pharma has appointed David Solomon as CEO. Solomon brings over 30 years of international leadership experience to the role. His past roles include CEO of Zealand Pharma and working on licensing agreements with Sanofi, Boehringer Ingelheim, Lilly, AbbVie and Helsinn. Solomon has also served on several biotech company boards.
Commit Biologics
Thomas Montgomery Andresen
Commit Biologics has appointed Thomas Montgomery Andresen as CEO. With over 20 years of experience building biotechnology ventures, Andresen most recently served as founding CEO of T-Cypher Bio. He also co-founded several biotech companies, including Torque Therapeutics.
Alvotech
Lisa Graver
Alvotech has appointed Lisa Graver as CEO. Previously, Graver served as CEO of Alvogen, where she worked for over 15 years in multiple leadership roles. Bringing expertise in leadership and operations, her other former roles include Vice President, Intellectual Property at Actavis Switzerland and Innovest Enterprises, and Director, Intellectual Property at Alpharma.
Angelini Pharma
Sergio Marullo
di Condojanni
Angelini Pharma has appointed Sergio Marullo di Condojanni as CEO. He has served as CEO of Angelini Industries since 2020, but the role has expanded to include Angelini’s pharmaceutical branch. Marullo di Condojanni is also the Chairman of Angelini Technologies, Director of Banca Aletti and an advisory board member of B20 Italy.
Cellbox
Bernd Muehlenweg
Cellbox has appointed Bernd Muehlenweg as Chief Business Officer and Chief Financial Officer. Most recently, Muehlenweg served as Senior Vice President and Global Head of Business Development, Cell Therapy at Evotec. Oher former roles include Chief Business Officer and Member of the Executive Board at Nanobiotix.
ViCentra
Reman McDonagh
ViCentra has appointed Reman McDonagh as Vice President, Global Marketing. Reman brings over 20 years of experience, having most recently held multiple senior leadership roles in marketing at Insulet. She has also held leadership roles at Roche, Medtronic and Cellnovo. Her areas of expertise include brand strategy and market development.
Novo Nordisk
Mette Bøjer Jensen and Elisabeth Dahl Christensen
Novo Nordisk announced Mette Bøjer Jensen and Elisabeth Dahl Christensen were re-elected as employee representatives to join the Board of Directors. Christensen has worked at Novo Nordisk for 25 years and Jensen has been at the company for over 22 years. They will join the board after the annual general meeting in March.
Novo Nordisk
Semsi Kilic Madsen and Désirée Jantzen Asgreen
Novo Nordisk announced Semsi Kilic Madsen and Désirée Jantzen Asgreen were newly elected as employee representatives to join the Board of Directors, effective 26 March 2026. Currently, Madsen is a Project Manager and Asgreen is Project Director. They will join the board after the annual general meeting in March.